Showing 4,861 - 4,880 results of 7,608 for search '"oncology"', query time: 0.07s Refine Results
  1. 4861
  2. 4862
  3. 4863
  4. 4864
  5. 4865
  6. 4866
  7. 4867
  8. 4868
  9. 4869
  10. 4870
  11. 4871

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  12. 4872
  13. 4873
  14. 4874
  15. 4875
  16. 4876

    IINS Vs CALLY Index: A Battle of Prognostic Value in NSCLC Patients Following Surgery by Cheng H, Ma J, Zhao F, Liu Y, Wu J, Wu T, Li H, Zhang B, Liu H, Fu J, He H, Zhu C, Ren H, Yang C, Qin S

    Published 2025-01-01
    “…Hao Cheng,1,* Jiao Ma,1,* Fengyu Zhao,2 Yiwei Liu,3 Jie Wu,4 Tao Wu,1 Hui Li,1 Boxiang Zhang,3 Hui Liu,5 Junke Fu,3 Haiqi He,3 Cailin Zhu,3 Hong Ren,3 Chengcheng Yang,2 Sida Qin3 1Department of Rehabilitation, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 3Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 4Department of Radiation Oncology, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi, People’s Republic of China; 5Biobank, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Sida Qin, Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, Shaanxi, 710061, People’s Republic of China, Tel +86 15388666585, Email qinsida@xjtu.edu.cn Chengcheng Yang, Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, Shaanxi, 710061, People’s Republic of China, Tel +86 17629260656, Email ccyang@xjtufh.edu.cnObjective: This research sought to assess the predictive potential of the inflammation-immunity-nutrition score (IINS) and the high-sensitivity C-reactive protein-albumin-lymphocyte (CALLY) index in individuals with NSCLC post-surgery.Methods: The study enrolled 506 patients with NSCLC undergoing R0 resection at the First Affiliated Hospital of Xi’an Jiaotong University. …”
    Get full text
    Article
  17. 4877
  18. 4878
  19. 4879
  20. 4880